Zoetis Inc.ZTS

Sell some

Avoid for now.

6 good· Earnings beat
6 to watch· Revenue slowing

$82.85+0.28 (+0.34%)

Price at 3:00 PM ET

After hours · opens in 17h 23m

NYSE · Healthcare · Pharmaceuticals · Large company

Tell me when ZTS moves 5% in a day

Read the full report on ZTS with a free account

The full report adds the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

What would change it

Sources

From the 10-Q for the quarter to Sep 30, reported Nov 5

Could move it to Keep

Next report

above8%
sales growth

−29.5% in a yearsince Nov 11, 2025

Earnings report

Latest results

Reported Nov 5 before the open

EPS: $1.75; vs $1.51 expected, beat by 16%
The stock: −8%; On Nov 5, usually 5.2%

The news behind our call

written Sep 25, 4:24 PM ETSep 25, 4:24 PM ET · 3 articles · 3 sources

Zoetis is scheduled to report earnings on February 12, 2026.
Zoetis generates strong operating profits and returns.
Zoetis’s business quality remains a strength.

What changed

From Yahoo Finance, Yahoo! Finance Canada and Zoetis Inc. via Nasdaq

ZTS reported earnings on Nov 5.

Analyst ratings shifted: 1 more buy, 1 fewer hold
6 buy, 10 hold, 0 sell, against 5 buy, 11 hold, 0 sell the month before.
Analysts · This month
Zoetis' Cytopoint Plus gets USDA License for 75-Day Canine Itch Relief
Today
Zoetis Receives USDA License for Cytopoint Plus™: The first and only Long-Acting Monoclonal Antibody Providing 75 days of Allergic Itch Relief in Dogs with Allergic Dermatitis
Yesterday
What are Wall Street analysts' target price for Zoetis stock?
Yesterday
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
Tuesday
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
Tuesday
ZTS Q3 earnings call highlights Competitive pressures and outlook
Monday
What Zoetis (ZTS) said on its Q3 earnings call
Sunday

Overview

In plain numbers

Revenue grew 0.9% from a year earlier, to $9.5B in the last twelve months.
It keeps 38 cents of every revenue dollar as operating profit.
It turned 24% of revenue into free cash flow: $2.2B in the last twelve months.
It owes $9.3B and holds $1.5B in cash and investments, so net debt is $7.7B.

Key figures

Revenue (TTM): $9.5B
Revenue growth, 1 year: +0.9%
Net income: $2.5B
EPS (diluted): $5.93
Gross margin: 71.7%
Operating margin: 37.9%

Return on equity: 57.6%
Return on capital: 26.4%
Debt / equity: 2.80
Current ratio: 2.35
Dividend yield: 2.56%
Buyback yield: 5.45%

Revenue by region

period ending Jun 30, 2026

United States$4.9B · 52%
International$4.5B · 48%

Key facts

Company value: $32.3B
Price / last year's earnings: 12.8×
Today's range: 82.4883.84
Past year's range: 68.64128.76

Yesterday's close: $82.57
Swings vs the market: 0.8×smaller
Dividend yield: 2.56%$2.12 a year

Compare ZTS with

ZTSvsBMYBristol-Myers Squibb Company